文献速递疼痛医学

内吗啡肽-1和-2在小鼠坐骨神经分支损伤神经病理痛模型中的抗异常疼痛作用

Antiallodynic Effects of Endomorphin-1 and Endomorphin-2 in the Spared Nerve Injury Model of Neuropathic Pain in Mice.
PubMed 文献 · Anesth Analg · 2017-01-01

该研究在小鼠坐骨神经分支损伤(SNI)模型上,观察中枢与局部给予内吗啡肽-1(EM-1)和内吗啡肽-2(EM-2)的抗机械异常疼痛作用。结果显示SNI术后14天患侧撤足阈值为0.061±0.02 g;侧脑室注射10 nmol EM-1和EM-2后5分钟峰值撤足阈值分别为0.92±0.36 g和0.87±0.33 g,均高于吗啡的0.46±0.20 g;二者中枢作用涉及不同μ阿片受体亚型,局部足底注射也产生镇痛。

要点

  • SNI小鼠术后14天出现持续机械异常疼痛,患侧撤足阈值0.061±0.02 g。
  • 侧脑室注射EM-1和EM-2(10 nmol)抗异常疼痛峰值阈值高于等剂量吗啡。
  • EM-1和EM-2中枢机制分别涉及μ1和μ2受体,EM-2还涉及内源性强啡肽A/κ受体。

核心结论

  • EM-1和EM-2中枢与局部给药均在小鼠SNI模型产生强效抗异常疼痛作用,且涉及不同阿片机制。

研究设计与样本

  • 小鼠SNI神经病理痛模型,保留腓肠神经,结扎并切断腓总神经和胫神经。
  • 采用Von Frey细丝测定机械异常疼痛行为,比较中枢与局部给药效果,并用阿片受体拮抗剂探讨机制。

主要发现

  • SNI术后14天患侧撤足阈值为0.061±0.02 g。
  • 侧脑室注射10 nmol EM-1和EM-2后5分钟峰值撤足阈值分别为0.92±0.36 g和0.87±0.33 g,高于吗啡的0.46±0.20 g。
  • 10 nmol EM-1和EM-2侧脑室给药对侧爪也产生显著抗异常疼痛作用,等剂量吗啡无显著作用。
  • EM-1和EM-2分别通过μ1和μ2受体介导中枢抗异常疼痛,EM-2还通过内源性强啡肽A释放作用于κ受体。
  • 足底但非皮下注射EM-1和EM-2产生局部镇痛,涉及μ1和μ2受体而非δ或κ受体。

关键数值与推荐

  • SNI术后14天患侧撤足阈值0.061±0.02 g。
  • 10 nmol EM-1和EM-2侧脑室给药后5分钟峰值撤足阈值分别为0.92±0.36 g和0.87±0.33 g,吗啡为0.46±0.20 g。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The spared nerve injury (SNI) model is a new animal model that can mimic several characteristics of clinical neuropathic pain. Opioids are recommended as treatment of neuropathic pain. Therefore, the present study was conducted to investigate the antinociceptive effects of endomorphin-1 (EM-1) and endomorphin-2 (EM-2) given centrally and peripherally in the SNI model of neuropathic pain in mice. METHODS: The SNI model was made in mice by sparing the sural nerve intact, when the other 2 of 3 terminal branches of the sciatic nerve (common peroneal and tibial nerves) were tightly ligated and cut. Von Frey monofilaments were used to measure the SNI-induced mechanical allodynia-like behavior. The antiallodynic effects of EM-1 and EM-2 were determined after central and peripheral administration in the SNI model of neuropathic pain. Also, the specific opioid receptor antagonists were used to determine the opioid mechanisms of EMs involved in neuropathic pain. Values were expressed as the mean ± standard deviation. RESULTS: Our results showed that the SNI mice developed prolonged mechanical allodynia-like behavior in ipsilateral paw after surgery, with the withdrawal threshold value being 0.061 ± 0.02 g after 14 days. EM-1 and EM-2 produced significant antiallodynic effects in ipsilateral paw after intracerebroventricular (i.c.v.) administration, more effective than that of morphine. The peak withdrawal thresholds of 10 nmol EM-1 and EM-2 determined at 5 minutes after injection were 0.92 ± 0.36 and 0.87 ± 0.33 g, respectively, higher than that of morphine (0.46 ± 0.20 g). Moreover, both EMs (10 nmol, i.c.v.) exerted significant antiallodynic effects in the contralateral paw, whereas no significant antinociceptive activity was seen after i.c.v. administration of morphine with equimolar dose. It was noteworthy that EM-1 and EM-2 produced antinociception through distinct μ1- and μ2-opioid receptor subtypes, and the EM-2-induced antiallodynia contained an additional component that was mediated by the release of endogenous dynorphin A, acting on κ-opioid receptor. In addition, the antiallodynic activities of peripheral administration of EM-1, EM-2, and morphine were also investigated. Intraplantar, but not subcutaneous administration of EM-1 and EM-2 also exhibited potent antinociception, establishing the peripheral and local effects. Both μ1- and μ2-opioid receptor subtypes, but not the δ- or κ-opioid receptors were involved in the peripheral antiallodynia of EMs. CONCLUSIONS: The present investigation demonstrated that both EM-1 and EM-2 given centrally and peripherally produced potent antiallodynic activities in SNI mice, and differential opioid mechanisms were involved.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Wang CL, Yang DJ, Yuan BY, et al. Antiallodynic Effects of Endomorphin-1 and Endomorphin-2 in the Spared Nerve Injury Model of Neuropathic Pain in Mice. Anesth Analg. 2017. PMID: 28787346. doi:10.1213/ANE.0000000000002318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。